Picture EBD Group BIO-Europe 2019 Partnering Open BEU2019 650x80px
Financing › Details

Blue Heron–Eurofins: investment, 201908 acquisition of Blue Heron Biotech by Eurofins Genomics LLC


Period Period 2019-08-06
Organisations Money taker Blue Heron Biotechnology Inc.
  Group Eurofins (Group)
  Money source Eurofins Genomics LLC (US)
  Group Eurofins (Group)
Products Product gene synthesis
  Product 2 synthetic biotechnology

Eurofins Genomics LLC. (8/6/19). "Press Release: Eurofins Genomics US Expands Gene Synthesis Capabilities with Acquisition of Blue Heron Biotech". Louisville, KY.

Eurofins Genomics LLC (US) announces that it has completed the acquisition of Blue Heron Biotech, a company specializing in advanced gene synthesis. The acquisition provides valuable synergies for both companies due to the inherent connection between their main product segments—oligonucleotides, sequencing and synthetic genes, and strengthens Eurofins Genomics offer in the synthetic biology market.

Blue Heron is renowned for their mastery of gene synthesis and sub cloning, which allows them to successfully construct sizable gene constructs that other suppliers simply cannot produce. Since DNA oligonucleotides play an integral role in genes, the deal will bolster Blue Heron's production capabilities as well as expand Eurofins Genomics gene portfolio into cloning and complex gene constructs.

Eurofins Genomics is a global leader in oligonucleotide synthesis, Sanger sequencing, next generation sequencing, and gene synthesis. It is the fastest service provider in the United States for DNA oligonucleotides and Sanger sequencing, largely due to Eurofins' proprietary synthesis technology and unique logistical advantages. Turnaround time (TAT) is a critical factor in today's highly competitive life sciences industry.

The announcement is especially interesting to researchers in the Synthetic Biology and Diagnostic sectors, which require large volumes of both genes and oligonucleotides. Eurofins Genomics is now uniquely positioned to provide holistic solutions to these customers. It even offers regulatory coverage for its products, including ISO 13485, ISO 9001, CLIA, CAP, GLP, and FDA compliance for the manufacturing of cGMP oligonucleotides used in ASR and IVD products for the clinical industry.

For more information, visit and

Eurofins Genomics LLC

North America: (+1) 1-800-688-2248
Europe: (+49) 8092 8289-77
Asia: (+81) 03-5492-7001

Investor Relations

Eurofins Scientific Group
Phone: + 32 2 766 1620

Notes for the editor:

About Eurofins Genomics

Eurofins Genomics is an international leader for genomic products and services. The company's key product lines include DNA and RNA synthesis, Sanger sequencing, gene synthesis, next generation sequencing, and applied genomics. Its strengths are speed, quality, and customer orientation.

As a member of the Eurofins group, the genomics division contains major offices and production facilities in the United States, Europe, and Asia. Its customers encompass a wide variety of industries including life science, pharma, diagnostics, food, agriculture, biotechnological and research markets around the world. Visit for more information.

Record changed: 2019-08-08


Picture [LSA] – The Business Web Portal 650x89px

More documents for Eurofins (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2019 Hamburg Germany BEU2019 650x80px

» top